Cadonilimab Plus Lenvatinib Shows Promising Antitumor Activity in Advanced Endometrial Cancer
In the phase II CLEAR-EC trial, combining the dual checkpoint inhibitor cadonilimab with lenvatinib yielded an objective response rate of ...
In the phase II CLEAR-EC trial, combining the dual checkpoint inhibitor cadonilimab with lenvatinib yielded an objective response rate of ...
Four-year follow-up data from the phase 3 RATIONALE-307 trial demonstrate sustained overall and progression-free survival improvements with first-line tislelizumab plus ...
A partitioned survival model indicates that first-line disitamab vedotin plus toripalimab is cost-effective compared to chemotherapy alone for HER2-overexpressing advanced ...
Clinicians have documented the first reported case of cadonilimab-associated hemophagocytic lymphohistiocytosis in a cervical cancer patient who experienced relapse during ...
A retrospective cohort study found that initial hepatic arterial infusion chemotherapy was associated with longer overall survival and higher response ...
A prospective phase II trial reports that orelabrutinib combined with sintilimab achieved a 60.7 percent response rate and a median ...
A retrospective study of 84 rectal cancer patients found that adding a PD-1 inhibitor to neoadjuvant chemoradiotherapy was associated with ...
A phase 2 trial reports that camrelizumab plus famitinib produced tumor shrinkage in 42.9 percent of patients with advanced pulmonary ...
A retrospective Chinese study of 102 elderly patients with inoperable esophageal squamous cell carcinoma found that a pretreatment absolute lymphocyte ...
A retrospective Nepalese cohort of 31 patients associated 20- or 40-milligram nivolumab with responses across advanced cancers, but uncontrolled evidence ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine